The discussed metabolic targets (PCSK9, MSTN, adipokines, and PPARs) therefore may represent new damage signals; existing studies on their modulation will provide a start-up platform to design innovative and combined strategies for personalized protection against late onset complications from I/R injury in myocardial infarction and major vascular surgery. This evidence concerns the gene MSTN and myocardial infarction.